Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Catumaxomab |
| Trade Name | |
| Synonyms | Removab |
| Drug Descriptions |
Catumaxomab is a trifunctional bispecific antibody that binds to Epcam and Cd3, and will bind to accessory immune cells such as macrophages, dendritic cells and natural killer cells, which redirects cytotoxic T-lymphocytes against tumor cells expressing Epcam, potentially inducing lysis of Epcam-expressing tumor cells (PMID: 32438548, PMID: 21188120). |
| DrugClasses | |
| CAS Registry Number | 509077-98-9 |
| NCIT ID | C62445 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Catumaxomab | Catumaxomab | 0 | 1 |